Tjip S Van Der Werf

List of Publications by Year
in descending order

214	7,866	57758	66911
papers	citations	44 h-index	78 g-index

217	217	217	7820
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
2	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
3	Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Nonâ€“Cystic Fibrosis Bronchiectasis. JAMA - Journal of the American Medical Association, 2013, 309, 1251.	7.4	421
4	Mycobacterium ulcerans infection. Lancet, The, 1999, 354, 1013-1018.	13.7	271
5	Efficacy of Corticosteroids in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 975-982.	5.6	262
6	Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet, The, 2010, 375, 664-672.	13.7	258
7	Association betweenFaecalibacterium prausnitziiand dietary fibre in colonic fermentation in healthy human subjects. British Journal of Nutrition, 2010, 104, 693-700.	2.3	172
8	Risk Factors for Buruli Ulcer Disease (Mycobacterium ulcerans Infection): Results from a Case-Control Study in Ghana. Clinical Infectious Diseases, 2005, 40, 1445-1453.	5.8	138
9	Histopathologic Features ofMycobacterium ulceransInfection. Emerging Infectious Diseases, 2003, 9, 651-656.	4.3	134
10	Beliefs and attitudes toward Buruli ulcer in Ghana.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 207-213.	1.4	131
11	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	5.8	116
12	Mycobacterium ulcerans disease. Bulletin of the World Health Organization, 2005, 83, 785-91.	3.3	114
13	Voriconazole metabolism is influenced by severe inflammation: a prospective study. Journal of Antimicrobial Chemotherapy, 2017, 72, 261-267.	3.0	113
14	PET/CT imaging of Mycobacterium tuberculosis infection. Clinical and Translational Imaging, 2016, 4, 131-144.	2.1	98
15	Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. Cell Reports, 2017, 18, 2752-2765.	6.4	98
16	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2018, 15, e1002591.	8.4	96
17	Paradoxical Responses After Start of Antimicrobial Treatment in Mycobacterium ulcerans Infection. Clinical Infectious Diseases, 2012, 54, 519-526.	5.8	91
18	The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 305-316.	2.9	86

#	Article	IF	Citations
19	Inflammation Is Associated with Voriconazole Trough Concentrations. Antimicrobial Agents and Chemotherapy, 2014, 58, 7098-7101.	3.2	81
20	Mycolactones and Mycobacterium ulcerans disease. Lancet, The, 2003, 362, 1062-1064.	13.7	78
21	Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine, 2015, 33, 3193-3199.	3.8	78
22	D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. European Journal of Internal Medicine, 2012, 23, 436-441.	2.2	76
23	The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. Nature Communications, 2020, 11, 2044.	12.8	76
24	Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet, The, 2020, 395, 1259-1267.	13.7	71
25	Comparative Study of the Sensitivity of Different Diagnostic Methods for the Laboratory Diagnosis of Buruli Ulcer Disease. Clinical Infectious Diseases, 2009, 48, 1055-1064.	5.8	68
26	Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. Respiratory Medicine, 2007, 101, 317-325.	2.9	66
27	Therapeutic vaccines for tuberculosisâ€"A systematic review. Vaccine, 2014, 32, 3162-3168.	3.8	66
28	CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. European Respiratory Journal, 2019, 53, 1802014.	6.7	66
29	Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review. Frontiers in Immunology, 2017, 8, 772.	4.8	64
30	Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Medical Microbiology and Immunology, 2013, 202, 95-104.	4.8	63
31	Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intensive Care Medicine, 2010, 36, 1394-1402.	8.2	61
32	Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. European Respiratory Journal, 2013, 42, 1614-1621.	6.7	59
33	Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. European Respiratory Journal, 2016, 47, 1867-1869.	6.7	59
34	Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2739.	3.0	56
35	Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis. Therapeutic Drug Monitoring, 2010, 32, 97-101.	2.0	55
36	Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 2013, 42, 504-512.	6.7	55

#	Article	IF	Citations
37	Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 2014, 43, 884-897.	6.7	55
38	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clinical Pharmacokinetics, 2019, 58, 747-766.	3.5	53
39	Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Tropical Medicine and International Health, 2005, 10, 1251-1257.	2.3	50
40	Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients. Clinical Pharmacokinetics, 2010, 49, 559-565.	3.5	50
41	Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin. American Journal of Tropical Medicine and Hygiene, 2009, 81, 82-87.	1.4	49
42	Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: A survey. Respiratory Medicine, 2007, 101, 2091-2098.	2.9	48
43	Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 912-920.	1.8	48
44	Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana. Vaccine Journal, 2005, 12, 125-129.	3.1	47
45	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. European Respiratory Journal, 2015, 46, 1205-1207.	6.7	47
46	In-vitro Activity of Avermectins against Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2015, 9, e0003549.	3.0	46
47	Dried Blood Spot Analysis Suitable for Therapeutic Drug Monitoring of Voriconazole, Fluconazole, and Posaconazole. Antimicrobial Agents and Chemotherapy, 2013, 57, 4999-5004.	3.2	45
48	End TB with precision treatment!. European Respiratory Journal, 2016, 47, 680-682.	6.7	45
49	Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged â‰¥65 years in the Netherlands. Clinical Therapeutics, 2010, 32, 1517-1532.	2.5	44
50	Diagnosis of tuberculosis through breath test: A systematic review. EBioMedicine, 2019, 46, 202-214.	6.1	44
51	Ultrasound of the lung: just imagine. Intensive Care Medicine, 2004, 30, 183-184.	8.2	43
52	Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathogens, 2018, 14, e1007297.	4.7	43
53	Buruli ulcer disease: prospects for a vaccine. Medical Microbiology and Immunology, 2009, 198, 69-77.	4.8	42
54	Cardiac troponin I release and cytokine response during experimental human endotoxaemia. Intensive Care Medicine, 2003, 29, 1598-1600.	8.2	41

#	Article	IF	Citations
55	Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli Ulcer Functional Limitation Score. Tropical Medicine and International Health, 2003, 8, 90-96.	2.3	41
56	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 703-710.	3.0	41
57	Low Caspofungin Exposure in Patients in Intensive Care Units. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	41
58	Global Epidemiology of Buruli Ulcer, 2010â€“2017, and Analysis of 2014 WHO Programmatic Targets. Emerging Infectious Diseases, 2019, 25, 2183-2190.	4.3	41
59	Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Tropica, 2003, 88, 51-56.	2.0	40
60	Pandemic Influenza and Hospital Resources. Emerging Infectious Diseases, 2007, 13, 1714-1719.	4.3	40
61	Analysis of an IS 2404 -Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. Journal of Clinical Microbiology, 2003, 41, 794-797.	3.9	38
62	Contribution of the Community Health Volunteers in the Control of Buruli Ulcer in BÃ©nin. PLoS Neglected Tropical Diseases, 2014, 8, e3200.	3.0	38
63	Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. Clinical Infectious Diseases, 2016, 62, civ921.	5.8	38
64	Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 4907-4913.	3.2	37
65	Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. British Journal of Nutrition, 2011, 105, 400-408.	2.3	35
66	Buruli Ulcer Control in a Highly Endemic District in Ghana: Role of Community-Based Surveillance Volunteers. American Journal of Tropical Medicine and Hygiene, 2015, 92, 115-117.	1.4	35
67	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 688-694.	2.5	35
68	Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respiratory Medicine, 2017, 131, 118-124.	2.9	34
69	Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. American Journal of Tropical Medicine and Hygiene, 2009, 81, 82-7.	1.4	34
70	Clarithromycin Significantly Increases Linezolid Serum Concentrations. Antimicrobial Agents and Chemotherapy, 2010, 54, 5418-5419.	3.2	31
71	Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 650-656.	9.1	31
72	Automated erythrocytapheresis in severe falciparum malaria: A critical appraisal. Acta Tropica, 2006, 98, 201-206.	2.0	30

#	Article	IF	Citations
73	Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis. Therapeutic Drug Monitoring, 2011, 33, 350-354.	2.0	30
74	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. European Respiratory Journal, 2016, 47, 1229-1234.	6.7	30
75	High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015. PLoS ONE, 2016, 11, e0154791.	2.5	30
76	Inhibition of p38 mitogen-activated protein kinase: Dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans*. Critical Care Medicine, 2002, 30, 841-845.	0.9	29
77	Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 196-201.	1.8	29
78	Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. Therapeutic Drug Monitoring, 2015, 37, 766-771.	2.0	29
79	Wound Care in Buruli Ulcer Disease in Ghana and Benin. American Journal of Tropical Medicine and Hygiene, 2014, 91, 313-318.	1.4	28
80	Determination of Bedaquiline in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry. Antimicrobial Agents and Chemotherapy, 2015, 59, 5675-5680.	3.2	28
81	Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. Journal of Antimicrobial Chemotherapy, 2016, 71, 2691-2703.	3.0	28
82	Chloroquine- and sulfadoxine-pyrimethamine-resistant falciparum malaria in vivo- a pilot study in rural Zambia. Tropical Medicine and International Health, 2000, 5, 692-695.	2.3	27
83	Fulminant necrotizing fasciitis and nonsteroidal antiinflammatory drugs. Intensive Care Medicine, 2001, 27, 1831-1831.	8.2	27
84	Persisting Social Participation Restrictions among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Neglected Tropical Diseases, 2014, 8, e3303.	3.0	27
85	Optimization of Standard In-House 24-Locus Variable-Number Tandem-Repeat Typing for Mycobacterium tuberculosis and Its Direct Application to Clinical Material. Journal of Clinical Microbiology, 2014, 52, 1338-1342.	3.9	27
86	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
87	A Genotypic Approach for Detection, Identification, and Characterization of Drug Resistance in Mycobacterium ulcerans in Clinical Samples and Isolates from Ghana. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1059-1065.	1.4	25
88	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. PLoS ONE, 2016, 11, e0149768.	2.5	25
89	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	25
90	Epidemiology of Staphylococcus aureus in a burn unit of a tertiary care center in Ghana. PLoS ONE, 2017, 12, e0181072.	2.5	25

#	Article	IF	Citations
91	Pandemic Influenza and Excess Intensive-Care Workload. Emerging Infectious Diseases, 2008, 14, 1518-1525.	4.3	24
92	Towards Rational Use of Antibiotics for Suspected Secondary Infections in Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2013, 7, e2010.	3.0	24
93	Low but Sufficient Anidulafungin Exposure in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 304-308.	3.2	24
94	Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
95	Sensitivity and specificity of an electronic nose in diagnosing pulmonary tuberculosis among patients with suspected tuberculosis. PLoS ONE, 2019, 14, e0217963.	2.5	24
96	Antidepressants self-poisoning and ICU admissions in a university hospital in The Netherlands. International Journal of Clinical Pharmacy, 2000, 22, 92-95.	1.4	23
97	Drug concentration in lung tissue in multidrug-resistant tuberculosis. European Respiratory Journal, 2013, 42, 1750-1752.	6.7	23
98	Ganciclovir therapeutic drug monitoring in transplant recipients. Journal of Antimicrobial Chemotherapy, 2021, 76, 2356-2363.	3.0	23
99	High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. International Journal of Mycobacteriology, 2016, 5, 226-230.	0.6	22
100	Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer. PLoS Neglected Tropical Diseases, 2016, 10, e0004594.	3.0	22
101	Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. Vaccine Journal, 2004, 11, 387-391.	2.6	21
102	Genetic Diversity of Staphylococcus aureus in Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0003421.	3.0	21
103	Former Buruli Ulcer Patientsâ€™ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management. PLoS Neglected Tropical Diseases, 2016, 10, e0005261.	3.0	21
104	Implementing tuberculosis entry screening for asylum seekers: the Groningen experience. European Respiratory Journal, 2016, 48, 261-264.	6.7	21
105	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300â€…mg linezolid dosages using in-house made capsules. European Respiratory Journal, 2019, 54, 1900580.	6.7	21
106	Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. European Respiratory Journal, 2015, 46, 444-455.	6.7	20
107	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. European Respiratory Journal, 2015, 45, 569-571.	6.7	20
108	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601724.	6.7	20

#	Article	IF	Citations
109	Comparison of 14 Molecular Assays for Detection of Mycobacterium tuberculosis Complex in Bronchoalveolar Lavage Fluid. Journal of Clinical Microbiology, 2013, 51, 3505-3511.	3.9	19
110	Bioavailability of voriconazole in hospitalised patients. International Journal of Antimicrobial Agents, 2017, 49, 243-246.	2.5	19
111	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. Clinical Infectious Diseases, 2018, 67, 1743-1749.	5.8	19
112	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	19
113	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. Clinical Pharmacokinetics, 2019, 58, 1445-1454.	3.5	19
114	Tuberculosis-Related Malnutrition: Public Health Implications. Journal of Infectious Diseases, 2019, 220, 340-341.	4.0	19
115	Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial. PLoS Neglected Tropical Diseases, 2014, 8, e2964.	3.0	18
116	Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. Mycoses, 2019, 62, 698-705.	4.0	17
117	Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
118	Yellow fever in a traveller returning from Suriname to the Netherlands, March 2017. Eurosurveillance, 2017, 22, .	7.0	17
119	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601612.	6.7	16
120	Pharmacologic management ofMycobacterium ulceransinfection. Expert Review of Clinical Pharmacology, 2020, 13, 391-401.	3.1	16
121	Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients. International Journal of Medical Microbiology, 2017, 307, 223-232.	3.6	15
122	Sensitivity and specificity of routine diagnostic work-up for tuberculosis in lung clinics in Yogyakarta, Indonesia: a cohort study. BMC Public Health, 2019, 19, 363.	2.9	15
123	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
124	Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	15
125	Perceptions on the Effectiveness of Treatment and the Timeline of Buruli Ulcer Influence Pre-Hospital Delay Reported by Healthy Individuals. PLoS Neglected Tropical Diseases, 2013, 7, e2014.	3.0	14
126	In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. European Respiratory Journal, 2014, 44, 808-811.	6.7	14

#	Article	IF	Citations
127	Validation of a visual analogue score (<scp>LRTIâ€VAS</scp>) in nonâ€<scp>CF</scp> bronchiectasis. Clinical Respiratory Journal, 2016, 10, 168-175.	1.6	14
128	Molecular Characterization of Staphylococcus aureus Isolates Transmitted between Patients with Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0004049.	3.0	12
129	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. European Respiratory Journal, 2016, 47, 1288-1290.	6.7	12
130	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. European Respiratory Journal, 2020, 55, 1901903.	6.7	12
131	Prone Positioning of Patients with Acute Respiratory Failure. New England Journal of Medicine, 2002, 346, 295-297.	27.0	11
132	Pandemic influenza and pediatric intensive care*. Pediatric Critical Care Medicine, 2010, 11, 185-198.	0.5	11
133	Physicians' and nurses' opinions on selective decontamination of the digestive tract and selective oropharyngeal decontamination: a survey. Critical Care, 2010, 14, R132.	5.8	11
134	Immunology in Tuberculosis: Challenges in Monitoring of Disease Activity and Identifying Correlates of Protection. Current Pharmaceutical Design, 2011, 17, 2853-2862.	1.9	11
135	Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. International Journal of Mycobacteriology, 2016, 5, S44-S45.	0.6	11
136	Methicillin Resistant Staphylococcus aureus Transmission in a Ghanaian Burn Unit: The Importance of Active Surveillance in Resource-Limited Settings. Frontiers in Microbiology, 2017, 8, 1906.	3.5	11
137	Unusual Cluster of HIV Type 1 Dual Infections in Groningen, The Netherlands. AIDS Research and Human Retroviruses, 2011, 27, 429-433.	1.1	10
138	Psychometric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Neglected Tropical Diseases, 2014, 8, e3254.	3.0	10
139	Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin. PLoS ONE, 2015, 10, e0119926.	2.5	10
140	Limited-Sampling Strategies for Anidulafungin in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 1177-1181.	3.2	10
141	Condition on arrival of transferred critically ill patients. Netherlands Journal of Medicine, 2000, 57, 180-184.	0.5	9
142	Abacavir/Lamivudine/Zidovudine Maintenance After Standard Induction in Antiretroviral Therapy-NaÃ¯ve Patients: FREE Randomized Trial Interim Results. AIDS Patient Care and STDs, 2010, 24, 361-366.	2.5	9
143	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. European Respiratory Journal, 2016, 48, 1800-1802.	6.7	9
144	The Application of Modern Dressings to Buruli Ulcers: Results from a Pilot Implementation Project in Ghana. American Journal of Tropical Medicine and Hygiene, 2016, 95, 60-62.	1.4	9

#	Article	IF	Citations
145	Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care. Therapeutic Drug Monitoring, 2016, 38, 313-318.	2.0	9
146	Lack of penetration of amikacin into saliva of tuberculosis patients. European Respiratory Journal, 2018, 51, 1702024.	6.7	9
147	Posaconazole trough concentrations are not influenced by inflammation: A prospective study. International Journal of Antimicrobial Agents, 2019, 53, 325-329.	2.5	9
148	In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1312-1321.	1.4	9
149	Assessment and Treatment of Pain during Treatment of Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0004076.	3.0	8
150	Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. European Respiratory Journal, 2016, 48, 1237-1239.	6.7	8
151	Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1011-1015.	1.4	8
152	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. European Respiratory Journal, 2016, 48, 932-934.	6.7	8
153	Neurological and functional recovery inÂtuberculosis patients with spinal cordÂinjury in The Netherlands. NeuroRehabilitation, 2017, 40, 439-445.	1.3	8
154	Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events. Aids, 2017, 31, 241-246.	2.2	8
155	Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa. PLoS Neglected Tropical Diseases, 2019, 13, e0007866.	3.0	8
156	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. European Respiratory Journal, 2020, 56, 2000803.	6.7	8
157	Antimicrobial Treatment of Mycobacterium ulcerans Infection. , 2019, , 203-220.		8
158	Dosing Ethambutol in Obese Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 4044-4045.	3.2	7
159	Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future. Antimicrobial Agents and Chemotherapy, 2015, 59, 2474-2474.	3.2	7
160	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. Respiratory Medicine, 2017, 132, 68-75.	2.9	7
161	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. European Respiratory Journal, 2018, 51, 1702490.	6.7	7
162	Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. European Respiratory Journal, 2019, 54, 1900373.	6.7	7

#	Article	IF	Citations
163	Non-surgical treatment of purulent pericarditis, due to non-encapsulated Haemophilus influenzae, in an immunocompromised patient. Netherlands Journal of Medicine, 1999, 55, 151-154.	0.5	6
164	Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. PLoS ONE, 2016, 11, e0166030.	2.5	6
165	Multidrug-Resistant Infections Among Hospitalized Adults With Community-Acquired Pneumonia In An Indonesian Tertiary Referral Hospital . Infection and Drug Resistance, 2019, Volume 12, 3663-3675.	2.7	6
166	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. Journal of Antimicrobial Chemotherapy, 2022, 77, 466-473.	3.0	6
167	Semirecumbent position in intensive care patients. Lancet, The, 2000, 355, 1013-1014.	13.7	5
168	Nutritional status and vitamin D3 during antimicrobial treatment. Lancet, The, 2011, 377, 1407-1408.	13.7	5
169	Serum Levels of Neopterin during Antimicrobial Treatment for Mycobacterium ulcerans Infection. American Journal of Tropical Medicine and Hygiene, 2013, 89, 498-500.	1.4	5
170	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. British Journal of Clinical Pharmacology, 2017, 83, 2325-2329.	2.4	5
171	Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. The Cochrane Library, 2018, 12, ED000128.	2.8	5
172	Variability and cost implications of three generations of the Roche LightCyclerÂ® 480. PLoS ONE, 2018, 13, e0190847.	2.5	5
173	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Therapeutic Drug Monitoring, 2019, 41, 59-65.	2.0	5
174	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentrationâ€“Time Curve of Linezolid for Different ABCB1 Genotypes. Therapeutic Drug Monitoring, 2019, 41, 253-254.	2.0	5
175	Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	5
176	A narrow escape: surviving massive pulmonary thromboembolism due to a persistently patent foramen ovale. Intensive Care Medicine, 2000, 26, 1400-1400.	8.2	4
177	p38-MAPK inhibition and endotoxin induced tubular dysfunction in men. Journal of Endotoxin Research, 2004, 10, 402-405.	2.5	4
178	Mycobacterium bovis infection in a young Dutch adult: transmission from an elderly human source?. Medical Microbiology and Immunology, 2012, 201, 397-400.	4.8	4
179	Strategy To Limit Sampling of Antituberculosis Drugs Instead of Determining Concentrations at Two Hours Postingestion in Relation to Treatment Response. Antimicrobial Agents and Chemotherapy, 2014, 58, 628-628.	3.2	4
180	Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. American Journal of Tropical Medicine and Hygiene, 2016, 94, 517-518.	1.4	4

#	Article	IF	Citations
181	Diagnostic Tests for Buruli Ulcer: Clinical Judgment Revisited. Clinical Infectious Diseases, 2018, 67, 835-836.	5.8	4
182	Risk factors contributing to a low darunavir plasma concentration. British Journal of Clinical Pharmacology, 2018, 84, 456-461.	2.4	4
183	Impact of radiographic screening of >34â€Š000 asylum seeker children. European Respiratory Journal, 2019, 54, 1900579.	6.7	4
184	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. BMJ Open, 2020, 10, e035350.	1.9	4
185	Corticosteroid therapy for the management of paradoxical inflammatory reaction in patients with pulmonary tuberculosis. Infection, 2020, 48, 641-645.	4.7	4
186	Clinical Relevance of Rifampicinâ€Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0182921.	3.2	4
187	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. BMJ Open, 2021, 11, e049777.	1.9	4
188	Atresia of a solitary pulmonary vein. Cardiology in the Young, 1995, 5, 350-353.	0.8	3
189	A systematic review of a single-class maintenance strategy with nucleoside reverse transcriptase inhibitors in HIV/AIDS. Antiviral Therapy, 2014, 19, 625-636.	1.0	3
190	Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C_{2h} measurements. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1695-1696.	1.2	3
191	Prolonged pyrexia and subtle skin lesions: polyarteritis nodosa. Lancet, The, 2016, 387, 1025-1026.	13.7	3
192	Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data. European Respiratory Journal, 2020, 56, 2001086.	6.7	3
193	Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana. BMC Infectious Diseases, 2021, 21, 331.	2.9	3
194	Pulmonary Tuberculosis Complicated by Bronchopleural Fistula. Tropical Doctor, 1989, 19, 31-33.	0.5	2
195	Lung transplantation for acute respiratory failure in rapidly progressive idiopathic pulmonary fibrosis. Transplant International, 2005, 18, 890-891.	1.6	2
196	An 18-Year-Old Man With Rapidly Progressive Multiorgan Failure After a Positive Mononucleosis Spot Test Result. Chest, 2006, 130, 291-295.	0.8	2
197	Antimicrobial drugs for Buruli ulcer â€“ Authors' reply. Lancet, The, 2010, 375, 1873-1874.	13.7	2
198	Oral treatment for patients with Buruli ulcer co-infected with HIV. Aids, 2014, 28, 797-798.	2.2	2

#	Article	IF	Citations
199	The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. PLoS Neglected Tropical Diseases, 2019, 13, e0007273.	3.0	2
200	Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review. BMJ Open, 2020, 10, e034940.	1.9	2
201	Artificial Intelligence to Guide Empirical Antimicrobial Therapyâ€“Ready for Prime Time?. Clinical Infectious Diseases, 2021, 72, e856-e858.	5.8	2
202	Community acquired pneumonia caused by M. tuberculosisâ€”diagnosis with CT. European Journal of Radiology, 1997, 24, 253-256.	2.6	1
203	Rifampicin and moxifloxacin for tuberculous meningitis. Lancet Infectious Diseases, The, 2013, 13, 568-569.	9.1	1
204	COPD-Lower Respiratory Tract Infection Visual Analogue Score (c-LRTI-VAS) validation in stable and exacerbated patients with COPD. BMJ Open Respiratory Research, 2021, 8, e000761.	3.0	1
205	Sarcoidosis presenting with glazy mucoid sputum and dyspnea: a case report. Journal of Medical Case Reports, 2021, 15, 232.	0.8	1
206	Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrugâ€“Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2018, 98, 376-378.	1.4	1
207	DIABETES IN RURAL WEST AFRICA. Lancet, The, 1987, 330, 638-639.	13.7	0
208	Availability of drugs to admitted patients in Yemeni public hospitals. European Journal of Clinical Pharmacology, 2002, 58, 79-80.	1.9	0
209	The Never Ending Struggle Against Development of Drug Resistance. Clinical Infectious Diseases, 2015, 61, 137-138.	5.8	0
210	Reply to Verhaeghe et al: Table 1.. Clinical Infectious Diseases, 2016, 63, 146-147.	5.8	0
211	Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?. European Respiratory Journal, 2019, 54, 1901597.	6.7	0
212	Random glucose sampling as screening tool for diabetes among disadvantaged tuberculosis patients residing in urban slums in India. ERJ Open Research, 2019, 5, 00025-2019.	2.6	0
213	1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?. Open Forum Infectious Diseases, 2019, 6, S560-S561.	0.9	0
214	Incidence of Thrombotic Events in Patients Admitted to a Dedicated Tuberculosis Center in the Netherlands. Blood, 2014, 124, 2860-2860.	1.4	0